Characterization of gut microbiome composition in T2D patients under SGLT2i and GLP1RA treatment

dc.contributor.advisorOrg, Elin, juhendaja
dc.contributor.advisorKrigul, Kertu Liis, juhendaja
dc.contributor.authorKazimova, Valida
dc.date.accessioned2023-06-21T08:08:08Z
dc.date.available2023-06-21T08:08:08Z
dc.date.issued2023
dc.description.abstractType 2 Diabetes (T2D) is a globally recognized health concern that has garnered significant research attention. This thesis work focuses on gut microbiome analysis in T2D patients who start taking two medications antidiabetic drugs: Empaglifrozin (SGLT2i) and Semaglutide (GLP1RA). Microbiome composition was analyzed using 16S rRNA sequencing. The research aims to enhance our understanding of how the gut microbiome is related to SGLT2/GLP1 drug intake, potentially leading to the development of personalized treatment approaches for improved patient outcomes.et
dc.identifier.urihttps://hdl.handle.net/10062/90897
dc.language.isoenget
dc.publisherTartu Ülikoolet
dc.rightsopenAccesset
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectType 2 Diabeteset
dc.subjectSGLT2iet
dc.subjectGLP1RAet
dc.subjectgut microbiomeet
dc.subjectEmpaglifrozinet
dc.subjectSemaglutideet
dc.titleCharacterization of gut microbiome composition in T2D patients under SGLT2i and GLP1RA treatmentet
dc.typeThesiset

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ValidaKazimova_S_T.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: